Pfizer (PFE) Long-Term Deferred Tax (2016 - 2025)
Pfizer (PFE) has disclosed Long-Term Deferred Tax for 17 consecutive years, with $9.7 billion as the latest value for Q4 2025.
- Quarterly Long-Term Deferred Tax rose 11.97% to $9.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.7 billion through Dec 2025, up 11.97% year-over-year, with the annual reading at $9.7 billion for FY2025, 11.97% up from the prior year.
- Long-Term Deferred Tax for Q4 2025 was $9.7 billion at Pfizer, down from $11.0 billion in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $13.3 billion in Q4 2022, with the low at $2.5 billion in Q2 2021.
- Average Long-Term Deferred Tax over 5 years is $7.4 billion, with a median of $7.9 billion recorded in 2024.
- The sharpest move saw Long-Term Deferred Tax skyrocketed 276.96% in 2021, then plummeted 72.06% in 2023.
- Over 5 years, Long-Term Deferred Tax stood at $9.0 billion in 2021, then surged by 47.67% to $13.3 billion in 2022, then tumbled by 72.06% to $3.7 billion in 2023, then skyrocketed by 133.73% to $8.7 billion in 2024, then increased by 11.97% to $9.7 billion in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $9.7 billion, $11.0 billion, and $10.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.